Kelly R. Carr practices in the area of corporate law with a focus on capital markets transactions. Her practice includes representing issuers, investments banks and underwriters in wide variety of public and private finance transactions of debt and equity securities, including public and private equity and equity-hybrid securities offerings, as well as high-yield, investment-grade debt offerings, and structured products offerings.
Ms. Carr is a 2018 graduate of Fordham University School of Law and a graduate of Syracuse University.
Admissions
- New York
Education
- Fordham University School of Law, J.D., 2018
- Syracuse University, B.S., 2015
Experience
- Duane Morris LLP
- Senior Associate, 2025-present
- Associate, 2021-2024 - Sidley Austin LLP
- Associate, 2018-2021
Representative Matters
Represented B. Riley Securities Inc. and Citigroup Global Markets Inc. as underwriters in a headline-making at-the-market transaction involving AMC Entertainment Holdings Inc. in which nearly $40 billion worth of AMC shares changed hands on Wall Street.
Represented Four Springs Capital Trust, a private REIT, in connection with Carlyle’s Global Credit platform’s financing up to $300 million in growth capital; Four Springs plans to use the funds to scale its portfolio that includes 122 properties across 29 states.
Represented JonesTrading Institutional Services LLC, acting as sales agent in a $150 million at the market equity offering of common stock for Overstock.com, Inc. (NASDAQ: OSTK), the online retailer and advancer of blockchain technology.
Represented Protagenic Therapeutics, Inc. (Nasdaq: PTIX), a pre-clinical biopharmaceutical company developing treatments for stress-related disorders, in its $13.2 million initial public offering and subsequent Nasdaq listing.
Advised the client regarding a free to play app where participants participate in weekly contests for prize money selecting results in NFL games, NASCAR, PGA Golf and English Premier League.
Represented H.C. Wainwright & Co., LLC, acting as sales agent in a $30 million at the market equity offering of common stock for XOMA Corp. (NASDAQ: RGLS). XOMA engages in the discovery, development, and licensing of innovative therapeutics derived from a unique platform of antibody technologies.